Regulatory FDA Approves First-Ever Gene Therapy for Treatment of Genetic Hearing Loss Under National Priority Voucher Program pharminent April 23, 2026
Market Access CMS Extends Medicare’s Short-Term Bridge Program for GLP-1 Obesity Drug Coverage pharminent April 23, 2026
Manufacturing Drugmaker AbbVie chooses North Carolina for $1.4B manufacturing campus pharminent April 23, 2026
Commercial Roche, facing biosimilar threats, puts faith in new cancer and obesity drugs pharminent April 23, 2026
Commercial Sanofi defends Dupixent patents, but execs insist it has nothing to do with CEO change pharminent April 23, 2026
Policy / Pricing CMS and FDA Announce RAPID Coverage Pathway to Accelerate Patient Access to Life-Changing Medical Devices pharminent April 23, 2026
Regulatory Unnamed pharma files citizen petition targeting FDA’s trove of rejection letters pharminent April 23, 2026
Pipeline Roche insists amylin obesity drug still valuable for patients who ‘don’t want side effects’ pharminent April 23, 2026
Clinical Data AAN 2026: J&J, Kyverna, Capricor and Praxis showcase practice-changing data pharminent April 23, 2026
Policy / Pricing Minnesota’s 340B Hospitals Make One Billion More From 340B Than They Spend on Uncompensated Care pharminent April 23, 2026
Manufacturing AbbVie opts for North Carolina to house $1.4bn manufacturing site pharminent April 23, 2026
Policy / Pricing FDA Releases Congressional Justification for FY 2027 Budget, Including Proposal Regarding Interchangeability of Biosimilars pharminent April 22, 2026
Market Access Medicare weight loss drug pilot on ice as insurers decline to contribute pharminent April 22, 2026
Clinical Data Moderna, after losing US funding, rebounds to start mRNA bird flu vaccine trial pharminent April 22, 2026
Policy / Pricing Trump’s psychedelics push a mixed blessing for neuropsychiatric companies, patients pharminent April 22, 2026
Clinical Data Ionis’ antisense drug stabilizes ultra-rare disease ahead of FDA decision pharminent April 22, 2026
M&A / Deals BioAegis and Prenosis partner for inflammatory disease therapies pharminent April 22, 2026
M&A / Deals BioAegis and Prenosis partner for inflammatory disease therapies pharminent April 22, 2026
Policy / Pricing Medicare obesity drug pilot extended after insurer pushback pharminent April 22, 2026
Clinical Data BioAge says early data suggest ‘best-in-class’ potential for inflammation drug pharminent April 21, 2026
M&A / Deals Tortugas takes neuro deep dive with $106M to develop Eisai, Hansoh programs pharminent April 21, 2026
